The prospective drug use review program must use guidelines established by the Oregon Health Authority that are based on the recommendations of the Pharmacy and Therapeutics Committee. The program must ensure that prior to the prescription being filled or delivered a review will be conducted by the pharmacist at the point of sale to screen for potential drug therapy problems resulting from the following: (1) Therapeutic duplication. (2) Drug-drug interactions, including serious interactions with nonprescription or over-the-counter drugs. (3) Incorrect dosage and duration of treatment. (4) Drug-allergy interactions. (5) Clinical abuse and misuse. (6) Drug-disease contraindications. Note: See note under 414.351.
‹ Prev All Oregon sections Next ›
Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.